My scientific training started at the University of Grenoble (France) with a Master’s degree in Exercise Physiology and Bioenergetics, followed by a PhD internship in the group of Pr. X. Leverve's lab where I studied the mechanisms of action of the antidiabetic drug metformin. After graduating, I joined one of the European leading group in the field of metabolism at the de Duve Institute (Pr. L. Hue, Brussels, Belgium) where I investigated the role of AMPK in the control of hepatic glucose metabolism and mitochondrial oxidative phosphorylation supported by a “Michel de Visscher” Research Fellowship. In 2007, I moved to the Netherlands and joined the Diabetes group of the department of Molecular Cell Biology of LUMC for driving several research lines aiming to identify novel therapeutic strategies for obesity and type 2 diabetes. Since 2012, I’m also appointed as Assistant Professor at the Leiden Immunoparasitology Group (LIPG) where I’m currently developing a new research line at the interface between immunology and metabolism.
My main interest is currently focused on studying the molecular mechanisms underlying the immunometabolic effects of parasitic infection and parasite-derived molecules using both in vitro and in vivo approaches in various rodent models or in humans. This original research line is aimed to identify new metabolically-active molecules and/or potential novel molecular targets involved in tissue-specific regulation of substrate metabolism and insulin sensitivity that can ultimately lead to future therapeutic opportunities for the treatment of metabolic disorders and type 2 diabetes.
Current research support
- Grant from European Association for the Study of Diabetes on the project: ‘Protective effects of parasite-derived molecules in metabolic disorders.’
- Co-applicant on a grant from Netherlands Royal Academy of Science and Arts (KNAW) on the project: ‘Helminth infections and type 2 diabetes mellitus in Indonesia. Integrating parasitological, immunological, behavioral and metabolic studies.’ Main applicant Prof. Dr. J.W.A. Smit.
- Co-applicant on a TopGrant grant from ZonMW on the project: ‘Helminth-derived glycoproteins and insulin sensitivity: from immunomodulatory properties to direct regulation of metabolic tissues.’ Main applicant Prof. Dr. M. Yazdanbakhsh.
Guigas B and Molofsky AB. A worm of one's own: how helminths modulate host adipose tissue function and metabolism. (2015). Trends in Parasitology, in press
Hussaarts L, Garcia-Tardon N, van Beek L, Heemskerk MM, Haeberlein S, van der Zon GC, Ozir-Fazalalikhan A, Berbee JF, Willems van Dijk K, van Harmelen V, Yazdanbakhsh M, Guigas B. Chronic helminth infection promotes adipose tissue M2 macrophages and improves insulin sensitivity in obese mice. (2015). FASEB J, in press
Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: from mechanism of action to therapy. (2014). Cell Metabolism. (2014). 20(6):953-66.
Hussaarts L, Yazdanbakhsh M, Guigas B. Priming dendritic cells for Th2 induction: lessons learned from helminths and implications for metabolic disorders. (2014). Frontiers in Immunology, 5:499.
Boon MR*, Bakker LEH*, Haks M, Joosten SA, van Schinkel LD, Wang Y, van Beek L, van Harmelen V, Ottenhof T, Willems van Dijk K, Guigas B, Jazet I* and Rensen PCN*. Short-term high-fat diet induces macrophage recruitment into skeletal muscle accompanied by reduced insulin signaling in healthy male subjects. (2015). Clinical Science, 128(2):143-51.
Geerling JJ*, Boon MR*, van der Zon GC, van den Berg SAA, van den Hoek AM, Lombes M, Princen HM, Havekes LM, Rensen PCN*, Guigas B*. Metformin reduces plasma cholesterol and triglyceride levels by promoting VLDL-triglyceride clearance by brown adipose tissue in mice. (2014). Diabetes, 63(3):880-91.
Hussaarts L, Smits HH, Schramm G, van der Ham AJ, van der Zon GC, Haas H, Guigas B, Yazdanbakhsh M. Rapamycin and helminth antigens: mTOR-dependent and -independent mechanisms to condition human dendritic cells for Th2 polarization. (2013). Immunology and Cell Biology, 91(7):486-9.
Wijngaarden MA, van der Zon GC, Willems van Dijk K, Pijl H, Guigas B. Effects of prolonged fasting on AMP-activated protein kinase signaling, metabolic gene expression and mitochondrial content in skeletal muscle from lean and obese individuals. (2013). AJP-Endocrinology & Metabolism, 304(9):E1012-21.
Stephenne X, Foretz M, Taleux N, van der Zon GC, Sokal EM, Hue L, Viollet B, Guigas B. Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status. (2011). Diabetologia, 54(12):3101-10.
De Leeuw Van Weenen JE, Parlevliet ET, Maechler P, Romijn JA, Ouwens DM, Pijl H*, Guigas B*. The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion mainly by direct activation of the α2-adrenergic receptors in beta cells. (2010). Biochemical Pharmacology, 79(12):1827-36.
Taleux N, De Potter I, Deransart C, Lacraz G, Favier R, Leverve X, Hue L, Guigas B. Lack of starvation-induced activation of AMP-activated protein kinase in the hypothalamus of the Lou/C rats resistant to obesity. (2008). International Journal of Obesity, 32(4):639-47.
Guigas B, Taleux N, Foretz M, Detaille D, Andreelli F, Viollet B, Hue L. AMP-activated protein kinase-independent inhibition of hepatic mitochondrial oxidative phosphorylation by AICA riboside. (2007). Biochemical Journal, 404(3):499-507.
Guigas B, Bertrand L, Taleux N, Foretz M, Wiernsperger N, Vertommen D, Andreelli F, Viollet B, Hue L. 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside and metformin inhibit hepatic glucose phosphorylation by an AMP-activated protein kinase-independent effect on glucokinase translocation. (2006). Diabetes, 55:865-874.
Guigas B, Detaille D, Chauvin C, Batandier C, De Oliveira F, Fontaine E, Leverve XM. Metformin inhibits permeability transition and cellular death: a pharmacological in vitro study. (2004). Biochemical Journal, 382(3):877-884.
* contributed equally
All publications can be found at Google Scholar
Leids Universitair Medisch Centrum
2333 ZA Leiden
Tel: +31 71 526 1328
2300 RC Leiden